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Summary Epidermal growth factor receptor (EGF-R) expression was assessed in 63 lung tumour samples
with a monoclonal antibody (EGF-R1) by indirect immunoperoxidase staining on cryostat sections. All 15
small cell lung cancer samples were negative whereas over 80% of the 48 non small cell lung cancer stained
positively.
In 30 bronchial biopsies two monoclonal antibodies against the cytoplasmic part of the EGF-R were
evaluated. These antibodies showed weaker staining than EGF-RI. No additional or enhanced staining as
compared with EGF-R1 was observed, suggesting a lack of enhanced expression of a truncated EGF-R
analogous to the v-erb-B oncogene product.
Monoclonal antibodies against the EGF-R may be helpful diagnostically in differentiating small cell from
non small cell lung cancer and may also be important in elucidating biological differences in primary lung
cancer.
During the last few years epidermal growth factor
(EGF) and its receptor (EGF-R) have been
intensively investigated in biological research (for
review see Hunter & Cooper, 1985). EGF-R is
present in a wide range of normal epithelial tissues
whereas EGF is found in normal human plasma
and in almost all human body fluids (Gusterson et
al., 1984: Kasselberg et al., 1985).
The role of this particular growth factor and its
receptor is still poorly understood both in normal
and in disease states. As a result of EGF binding to
its specific receptor there is increased DNA
synthesis as well as other events such as cell
proliferation, differentiation and repair of damaged
epithelial tissue (Schlessinger et al., 1983; King et
al., 1985). Conversely in cells possessing high
numbers of EGF-R (A431 derived, vulval
squamous carcinoma) a retardation of proliferation
after incubation with EGF has been noted (Barnes,
1982).
A close similarity between the sequence of the
v-erb-B oncogene of AEV-H (a strain of the avian
erythroblastosis virus) and the cytoplasmic and
transmembrane part of the EGF-R (truncated
EGF-R) has been found (Downward et al., 1984).
It was hypothesised that an inappropriate activa-
tion of the human erb-B gene either by truncation
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or overexpression plays a role in the development
of malignancy (Newmark, 1984). This hypothesis is
supported by preliminary studies which have shown
an increased number of EGF-R in various malig-
nant tumours (Hendler & Ozanne, 1984; Libermann
et al., 1984; Neal et al., 1985; Gusterson et al.,
1985; Gullick et al., 1986). In human breast cancer
EGF-R was increased in metastases (Fitzpatrick et
al., 1984) and was inversely related to the steroid
receptor status (Sainsbury et al., 1985).
In lung cancer there have been only a few reports
using radioimmunoassay techniques involving small
numbers of cases, probably because EGF-R assess-
ment requires unfixed tissue (Hendler & Ozanne,
1984; Sherwin et al., 1981). We have collected
biopsies of 63 patients with lung cancer and
assessed their EGF-R expression using an indirect
immunoperoxidase method with a monoclonal
antibody against the EGF-R (Waterfield et al.,
1982). In 30 of these 63 patients, two new mono-
clonal antibodies against the cytoplasmic part of
the EGF-R were evaluated. This was done in order
to determine whether tumour samples ever
expressed truncated EGF-R which would be a
homologue of the v-erb-B oncogene product (see
Figure 1).
Materials and methods
Lung tumour samples were obtained from 25
patients undergoing thoracotomy and a further 42
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at bronchoscopy. Of the latter, 4 patients had
pulmonary metastases from an extrapulmonary
primary (1 breast cancer, 1 ovarian cancer and 2
non-Hodgkin lymphoma metastases). A further 20
bronchoscopic tissue samples with no or very few
tumour cells were also evaluated. Of the total 63
patients with primary lung cancer the cell types are
as follows: 15 small cell lung cancer (SCLC), 42
squamous cell lung cancer, 4 adenocarcinoma, 1
pleomorphic adenoma and 1 large cell carcinoma.
There were 55 men and 8 women, with a mean age
of 62 years. Placental tissue served as a positive
control in EGF-R1 experiments and in addition
cervical squamous epithelium was used for EGF-
RF4 and EGF-RDIO, monoclonal antibodies
against a synthetic peptide from the cytoplasmic
domain of the EGF-R (residues 985-996). All three
monoclonal antibodies against the EGF-R were
also tested in A431 cells (kindly provided by Ana
Schor). In each experiment a negative control using
PBS instead of the primary antibody was used.
In the cryostat, frozen sections (6pm thick) were
cut from lung biopsies obtained as described. All
samples were snap frozen in liquid nitrogen and
stored at - 190°C. The sections were placed on
slides treated with poly 1-lysine (0.01%). Cut
sections were kept in the cryostat cabinet until
cutting was complete. One section from each
sample was stained with haematoxylin and eosin.
Sections were taken from cold cabinet and placed
in acetone/chloroform (1:1) for 5min, and then
washed in PBS for 2min. Endogenous peroxidase
was blocked with 0.3% hydrogen peroxide in PBS
for 10min, followed by 2 x 5min washes in PBS.
The sections were then covered with normal rabbit
serum/PBS 1:5 for 10min and excess serum drained
from and wiped off the slides but keeping the
sections moist. The sections were thereafter covered
with EGF-R antibody diluted 1 in 50 with diluted
rabbit serum. They were left for 90min and washed
in PBS for 2 x 5min after which they were covered
in diluted rabbit serum for 10min. Excess serum
was drained from the slides but the sections were
again kept moist and covered with secondary
antiserum (peroxidase conjugated rabbit anti-mouse
antiserum) diluted 1/20 with diluted rabbit serum,
left for 60min and then washed in PBS for
2 x 5 min. Finally, peroxidase activity was demon-
strated using diaminobenzidine solution (DAB),
followed by counterstaining with haematoxylin.
The histological sections were evaluated by two
observers and the degree of staining scored as
follows: 0=negative; + <25% positive stained
tumour cells; + + =25-50% and + + + >50%.
In cases where observers disagreed the sections
were studied together and agreement was reached.
The chi-square test was used to analyse the
results.
External domain including
the ligand binding site
"Truncated" EGF-R:homologous /r t ,/ ' \ to the v-erb B oncogene product
mAb EGF-R,' , % \\(Dnoard 1984)
/ L Cell mAb EGF-RF4 and mAb EGF-RD,0 / Cell
membrane
Figure 1 The transmembrane EGF-R and the three
monoclonal antibodies (mAb) used in this study. EGF-
RI mAb: (Waterfield et al., 1982). IgG2b subclass.
Antiprotein mAb to the external domain of the EGF-
R but does not compete for EGF-binding. EGF-RF4
mAb and EGF-RD1O mAb: (Gullick et al., 1986).
IgGI subclass. Antipeptides mAb to a synthetic
peptide from near the C-terminus of EGF-R, (residues
985-996).
Results
The results of the staining with the EGF-R1
monoclonal antibody are summarised in Table Ia.
There is an obvious difference of EGF-R expression
between the SCLC with no positive staining
compared to the other lung primaries where 85% of
cases were positively stained (p<0.00001).
Most squamous cell bronchial carcinoma were
strongly positive in most of the tissues examined
(Figure 2a). Often negative or weakly stained areas
were adjacent to strongly positive areas. The 8
negatively stained squamous cell carcinoma were
all tiny biopsies. Two moderately well differentiated
adenocarcinomas of the lung were strongly positive
(Figure 2b); one poorly differentiated adeno-
carcinoma was also positive whereas another was
negative. In these samples the staining pattern was
homogeneous. A pleomorphic adenoma of the lung
and one large cell carcinoma were also positively
stained. In the SCLC samples foci of slightly
positively stained cells were often found. The cells
of these groups in general contained more
cytoplasm.
Tissue of 4 lung metastases were also examined:
two non Hodgkin lymphomas and a breast cancer
metastasis were negative whereas a metastasis from
an ovarian carcinoma was positive.
In a further 20 lung biopsies no malignant cells,
or only very few were found. In these samples, as
well as in lung tissue adjacent to the tumour,
squamous metaplasia and often macrophages
stained positively. Also serous and mucinous glands
often contained positive areas of EGF-R
expression, as well as basal bronchiolar epithelial
cells.
The two monoclonal antibodies against the
cytoplasmic part of the EGF-R (EGF-RF4 andEPIDERMAL GROWTH FACTOR RECEPTOR 267
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Figure 2 (a) Squamous cell carcinoma of the lung (Pt 16), moderately well differentiated, with strong
positive staining of the tumour cell membrane and less of the cytoplasm. In areas of early keratinisation (left
of the middle) the staining is less intensive (magnification: x 160). (b) Adenocarcinoma of 'the lung (Pt 19),
positively stained. The staining pattern is slightly granular and more intense on the cell menirane (EGF-Rl;
magnification: x 320). (c) Small cell lung cancer (Pt 47), no positive staining (EGF-R1; magnification: x 320).
(d) Squamous cell carcinoma of the lung (Pt 5), tiny bronchial biopsy which shows intensive staining of the
cell membrane and only slight positivity of the cytoplasm (EGR-Rl; magnification: x 320).
EGF-RD1O) were evaluated in 30 lung cancer
biopsies and showed less intensive staining than
with the EGF-RI antibody (Table Ib). EGF-RDlO
was significantly weaker than EGF-RF4 when used
at the same concentration. Positive EGF-RF4
staining was demonstrated in 19 of 22 EGF-Rl
positive squamous cell tumours, the pattern of
staining being similar although weaker. In no
instance was a positive result obtained with these
two antibodies in an EGF-R1 negative tumour
sample.
Discussion
Small cell lung cancer is biologically different from
other primary lung tumours since it often shows
early widespread disease, a high growth fraction
and a short cell doubling time. However, it does
have a high response rate to chemotherapy. There,
fore in oncological practice the classification of
SCLC versus NSCLC is important in patient
management.
In our hands immunohistochemical analysis with
monoclonal antibodies against the EGF-R showed
no positive staining in any of the 15 tissue samples
from SCLC cases whereas in all groups of NSCLC
examined the majority of tumours were positive.
Therefore for diagnostic purposes monoclonal
antibodies against EGF-R may be important for
the future. Moreover the lack of increased EGF-R
expression in SCLC may reflect a more funda-
mental difference from other primary lung tumours.
Foci of faintly positive cells were seen in SCLC268 T. CERNY et al.
Table Ia Indirect immunoperoxidase staining with EGF-Rl in lung tumour samples
EGF-R1 Total
Tumour type 0 + + + + + + positive
Squamous cell lung cancer (n=42) 6a 0 8 28 36
Adenocarcinoma (n=4) 1 0 0 3 3
Pleomorphic adenoma (n 1) 0 0 0 1 1
Large cell lung cancer (n=1) 0 0 0 1 1
Small cell lung cancer (SCLC) (n= 15) 15b 0 0 0 0
Table lb Indirect immunoperoxidase staining with EGF-RF4 and EGF-RDl0
EGF-RF4 EGF-RDIO
Tumour type 0 + ++ +++ 0 + ++ +++
Squamous celllung cancer (n=23)c 4 0 14 5 10 6 7 0
Large cell lung cancer (n= 1) 0 0 1 0 1 0 0 0
Adenocarcinoma (n= 1) 0 0 1 0 1 0 0 0
Small cell lung cancer (n=5) 5 0 0 0 5 0 0 0
The histological sections were evaluated by two observers and the degree of staining scored as
follows:
0=negative;
+ = <25% positive stained tumour cells;
+ + =25-50%;
+++=>50-100%;
nd=not done.
'All these samples were tiny biopsies.
bSmall foci ofpositive stained cells often seen.
C22 of these samples were positive with EGF-R1.
samples and these cells showed a decreased
nuclear/cytoplasmic ratio. This may reflect
squamous or adenocarcinomatous differentiation in
a few cell groups. It may be that all bronchogenic
carcinomas have a common cell of origin and
indeed on close inspection especially with mono-
clonal antibodies one can find all the main cell
types in selected tumours (Gatter et al., 1985).
None of the SCLC samples showed detectable
expression of the cytoplasmic part of the EGF-R
(truncated EGF-R) as assessed by the two new
monoclonal antibodies (EGF-RD1O and EGF-RF4).
Therefore immunohistochemically no increased
expression of a truncated EGF receptor analogous
to the v-erb-B gene product could be found in
this series.
Forty-one of the 48 NSCLC samples showed
positive staining with EGF-RI. The group included
squamous, adeno and large cell bronchial
carcinoma as well as a pleomorphic adenoma. The
conclusion of an earlier report (Hendler & Ozanne,
1984) that adenocarcinomas may be distinguished
from squamous cell carcinomas by their EGF-R
expression could not be confirmed in our series.
Squamous cell carcinoma did not stain
homogeneously and negative areas were seen. This
may reflect different cell clones or lack of
expression of EGF-R in some cells. The six
negative squamous cell tumour samples in our
series were all tiny biopsies and may not have been
representative of the overall staining pattern.
However, none of the thoracotomy samples of the
squamous cell carcinomas were negative. The
inevitablecrushingofthebiopsyduringbronchoscopy
could have destroyed the cell membrane leading to
negative staining in these very small samples.
Interestingly one metastasis of an ovarian
carcinoma was positive, in keeping with recent
findings (Gullick et al., 1986) whereas one
pulmonary breast carcinoma metastasis and two
non Hodgkin lymphomas were negative. A further
20 lung tissue samples with few or no malignant
cells showed positive staining of squamous
metaplasia. Serous and mucinous bronchial glands
as well as macrophages were invariably positively
stained. Recently a new v-erb-B related gene has
been found in a human mammary carcinoma and
other tumours and the immunological properties ofEPIDERMAL GROWTH FACTOR RECEPTOR 269
its oncogene product in comparison to the EGF-R
has yet to be determined (King et al., 1985;
Yamamoto et al., 1986; Bargmann et al., 1986).
We conclude that immunohistochemistry with
monoclonal antibodies against EGF-R may play a
role for diagnostic purpose by differentiating,
between SCLC and NSCLC and may provide new
insight in biological differences of primary lung
cancers.
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